Articles by Susan L. Ettner, PhD
Physician Variation in Lung Cancer Treatment at the End of Life
ByJonas B. Green, MD, MPH, MSHS,Martin F. Shapiro, MD, PhD,Susan L. Ettner, PhD,Jennifer Malin, MD, PhD,Alfonso Ang, PhD,Mitchell D. Wong, MD, PhD Patients receiving care for advanced non—small cell lung cancer in small, independent oncology practices are more likely to receive chemotherapy in the last 30 days of life.
Optimizing Enrollment in Employer Health Programs: A Comparison of Enrollment Strategies in the Diabetes Health Plan
ByLindsay B. Kimbro, MPP,Jinnan Li, MPH,Norman Turk, MS,Susan L. Ettner, PhD,Tannaz Moin, MD, MBA, MSHS,Carol M. Mangione, MD,O. Kenrik Duru, MD, MSHS An automatic enrollment strategy for health insurance programs may not only increase the total number of enrollees but may also decrease some enrollment disparities.
Medical Costs Associated With Type 2 Diabetes Complications and Comorbidities
ByRui Li, PhD,Dori Bilik, MBA,Morton B. Brown, PhD,Ping Zhang, PhD,Susan L. Ettner, PhD,Ronald T. Ackermann, MD,Jesse C. Crosson, PhD,William H. Herman, MD A large proportion of medical costs for type 2 diabetes are attributable to complications and comorbidities, especially end stage renal disease with dialysis or kidney transplantation.
Adoption and Use of Stand-Alone Electronic Prescribing in a Health Plan-Sponsored Initiative
ByJoshua M. Pevnick, MD, MSHS,Steven M. Asch, MD, MPH,John L. Adams, PhD,Soeren Mattke, MD, DSc,Mihir H. Patel, PharmD,Susan L. Ettner, PhD,Douglas S. Bell, MD, PhD In a health plan–sponsored e-prescribing initiative, participating PCPs' mean e-prescribing rate was 1 prescription per 4 pharmacy claims, but some PCPs achieved high use.
Cost-sharing for antihypertensive drugs had the most significant and negative relationship with adherence for low adherers.
Cost Evaluation of a Coordinated Care Management Intervention for Dementia
ByO. Kenrik Duru, MD, MSHS,Susan L. Ettner, PhD,Stefanie D. Vassar, MS,Joshua Chodosh, MD, MSPH,Barbara G. Vickrey, MD, MPH A dementia care management program proven to improve quality and outcomes showed a statistically nonsignificant cost offset (both payer and societal perspectives) over 18 months.
Medicare Part D Coverage Gap and Diabetes Beneficiaries
ByJulie A. Schmittdiel, PhD,Susan L. Ettner, PhD,Vicki Fung, PhD,Jie Huang, PhD,Norman Turk, MS,Elaine S. Quiter, MS,Bix E. Swain, MS,John T. Hsu, MD, MBA, MSCE,Carol M. Mangione, MD, MSPH When diabetic patients in 2 Medicare Advantage Part D plans reached the 2006 coverage gap, overall drug costs dropped as out-of-pocket costs increased.
Physician Perception of Reimbursement for Outpatient Procedures Among Managed Care Patients With Diabetes Mellitus
ByCatherine Kim, MD, MPH,Edward F. Tierney, MPH,William H. Herman, MD, MPH,Carol M. Mangione, MD, MSPH,K. M. Venkat Narayan, MD, MPH, MBA,Robert B. Gerzoff, MS,Dori Bilik, MBA,Susan L. Ettner, PhD Perception of reimbursement was associated with electrocardiography but not with other common outpatient procedures. Future research should investigate how associations change with perceived reimbursement amount.
Effect of Cost-sharing Changes on Self-monitoring of Blood Glucose
ByAndrew J. Karter, PhD,Melissa M. Parker, MS,Howard H. Moffet, MPH,Ameena T. Ahmed, MD, MPH,James Chan, PharmD, PhD,Michele M. Spence, PhD,Joe V. Selby, MD, MPH,Susan L. Ettner, PhD Physicians' Perceptions of Relevant Prescription Drug Costs: Do Costs to the Individual Patient or to the Population Matter Most?
ByWilliam H. Shrank, MD, MSHS,George J. Joseph, MS,Niteesh K. Choudhry, MD, PhD,Henry N. Young, PhD,Susan L. Ettner, PhD,Peter Glassman, MBBS, MSc,Steven M. Asch, MD, MPH,Richard L. Kravitz, MD, MSPH Do the Incentives in 3-Tier Pharmaceutical Benefit Plans Operate as Intended? Results From a Physician Leadership Survey
ByWilliam H. Shrank, MD, MSHS,Henry N. Young, PhD,Susan L. Ettner, PhD,Peter Glassman, MBBS, MSc,Steven M. Asch, MD, MPH,Richard L. Kravitz